ANRS CO2 SEROCO/HEMOCO - Multicentric Cohort of HIV Positive Patients 
Head :
Meyer Laurence, U822
Last update : 01/01/2019 | Version : 2 | ID : 60080
| General | |
| Identification | |
| Detailed name | Multicentric Cohort of HIV Positive Patients |
| Sign or acronym | ANRS CO2 SEROCO/HEMOCO |
| CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation | CNIL no. 87-108 (17/11/1987) |
| General Aspects | |
| Medical area |
Infectious diseases |
| Health determinants |
Geography Social and psychosocial factors |
| Keywords | AIDS stage, morbidity, mortality, health events |
| Scientific investigator(s) (Contact) | |
| Name of the director | Meyer |
| Surname | Laurence |
| Address | 94276 LE KREMLIN BICÊTRE |
| Phone | +33 (0)1 45 21 23 34 |
| laurence.meyer@inserm.fr | |
| Unit | U822 |
| Organization | INSERM - Institut National de Santé et Recherche |
| Collaborations | |
| Participation in projects, networks and consortia |
Yes |
| Details | Involved in cohort network: COHORTES AC7, HEPAVIH - international: COHERE, EUROPEAN COHORT OF INJECTION DRUG USERS (Mr. PRINS, NETHERLANDS), CASCADE Involved in a European project: Cascade, Cohere. |
| Funding | |
| Funding status |
Public |
| Details | ANRS |
| Governance of the database | |
| Sponsor(s) or organisation(s) responsible | Agence Nationale de Recherches sur le Sida et les hépatites virales (ANRS) |
| Organisation status |
Public |
| Additional contact | |
| Main features | |
| Type of database | |
| Type of database |
Study databases |
| Study databases (details) |
Cohort study |
| Database recruitment is carried out by an intermediary |
A selection of health institutions and services |
| Database recruitment is carried out as part of an interventional study |
No |
| Additional information regarding sample selection. | Inclusion method: Prospective Inclusion cut-off date: 01/01/2001 |
| Database objective | |
| Main objective | General objective: to investigate spontaneous HIV disease progression and the treatment response of haemophiliac (HEMOCO) or non-haemophiliac (SEROCO) subjects. The prognostic role of markers, in particular CD4, HIV-RNA and HIV-DNA. |
| Inclusion criteria |
SEROCCO: Seropositive HIV-1 patients (ELISA test confirmed by Western blot) with known date of contamination or whose HIV status is less than a year old (period between first positive sample date and the date the patient is enrolled in survey) and who do not have AIDS at baseline; attending physicians from centres participating in the survey; who are 18 years old or over and have given their informed consent.
HEMOCO: HIV-seropositive haemophiliacs (ELISA test confirmed by Western blot); attending physicians from centres participating in the survey, who are 3 years old and over and have given their informed consent. Consent is signed by the parties with parental authority of dependent minors or by the legal guardians of minors under tutelage. |
| Population type | |
| Age |
Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) |
| Population covered |
Sick population |
| Gender |
Male Woman |
| Geography area |
Regional |
| French regions covered by the database |
Île-de-France Provence - Alpes - Côte d'Azur |
| Detail of the geography area | Paris regions and PACA (21 centres). |
| Data collection | |
| Dates | |
| Date of first collection (YYYY or MM/YYYY) | 01/1988 |
| Date of last collection (YYYY or MM/YYYY) | 01/2009 |
| Size of the database | |
| Size of the database (number of individuals) |
[1000-10 000[ individuals |
| Details of the number of individuals | - 1551 (SEROCO) - 197 (HEMOCO) |
| Data | |
| Database activity |
Data collection completed |
| Type of data collected |
Clinical data Declarative data Biological data |
| Clinical data (detail) |
Direct physical measures Medical registration |
| Details of collected clinical data | Clinical examination at baseline and every 6-month follow-up. Information collected during clinical examination: clinical, virological, immunological data, initiation and interruption of several antiretroviral drugs. |
| Declarative data (detail) |
Paper self-questionnaire Face to face interview |
| Details of collected declarative data | Information collected by self-administered questionnaire: sexual behaviour. Interview questionnaire at baseline and every 6-month follow-up. Information collected during interview: behavioural practices. |
| Biological data (detail) | Type of samples taken: blood. |
| Presence of a biobank |
Yes |
| Contents of biobank |
Serum Fluids (saliva, urine, amniotic fluid, …) |
| Details of biobank content | Serum bank, lymph bank, cell bank. |
| Health parameters studied |
Health event/morbidity Health event/mortality Health care consumption and services |
| Care consumption (detail) |
Medicines consumption |
| Procedures | |
| Data collection method | Self-administered questionnaire: entry from a paper questionnaire; Interviews: entry from a paper questionnaire; Clinical examinations: handwritten Biological analysis: handwritten |
| Quality procedure(s) used | Consistency request after electronic data is recorded. Missing data is managed by returning to source record. Physician reminder for follow-up visits. Patients are informed about the use of their data. |
| Participant monitoring |
Yes |
| Details on monitoring of participants | Every 6 months. |
| Links to administrative sources |
Yes |
| Linked administrative sources (detail) | CépiDc, RNIPP, InVS |
| Promotion and access | |
| Promotion | |
| Link to the document | http://tinyurl.com/HAL-ANRS-CO2 |
| Description | List of publications in HAL |
| Link to the document | http://tinyurl.com/Pubmed-ANRS-CO2 |
| Description | List of publications in Pubmed |
| Access | |
| Terms of data access (charter for data provision, format of data, availability delay) |
Data may be used by academic teams.
Data may not be used by industrial teams. |
| Access to aggregated data |
Access on specific project only |
| Access to individual data |
Access on specific project only |
